(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
4 May 2006 (04.05.2006)

PCT

(10) International Publication Number
WO 2006/046031 A1

(51) International Patent Classification:
C07D 495/04 (2006.01) *A61K 31/519* (2006.01)

(21) International Application Number:
PCT/GB2005/004129

(22) International Filing Date: 25 October 2005 (25.10.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0423653.5 25 October 2004 (25.10.2004) GB

(71) Applicant *(for all designated States except US)*: **PIRAMED LIMITED** [GB/GB]; 957 Buckingham Avenue, Slough, Berkshire SL1 4NL (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **SHUTTLEWORTH, Stephen, J.** [GB/GB]; 957 Buckingham Avenue, Slough, Berkshire SL1 4NL (GB). **FOLKES, Adrian, J.** [GB/GB]; 957 Buckingham Avenue, Slough, Berkshire SL1 4NL (GB). **CHUCKOWREE, Irina, S.** [MU/GB]; 957 Buckingham Avenue, Slough, Berkshire SL1 4NL (GB). **WAN, Nan, Chi** [CN/GB]; 957 Buckingham Avenue, Slough, Berkshire SL1 4NL (GB). **HANCOX, Timothy, C.** [GB/GB]; 957 Buckingham Avenue, Slough, Berkshire SL1 4NL (GB). **BAKER, Stewart, J.** [GB/GB]; 957 Buckingham Avenue, Slough, Berkshire SL1 4NL (GB). **SOHAL, Sukhjit** [GB/GB]; 957 Buckingham Avenue, Slough, Berkshire SL1 4NL (GB). **LATIF, Mohammed, A.** [GB/GB]; 957 Buckingham Avenue, Slough, Berkshire SL1 4NL (GB).

(74) Agents: **KEEN, Celia, Mary** et al.; J.A. Kemp & Co., 14 South Square, Gray's Inn, London WC1R 5JJ (GB).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

[Continued on next page]

(54) Title: PHARMACEUTICAL COMPOUNDS



(I)



(II)

(57) **Abstract:** Fused pyrimidines of formula (I); wherein A represents a thiophene or furan ring; n is 1 or 2; R^1 is a group of formula (II); wherein m is 0 or 1; R^{30} is H or C_1-C_6 alkyl; R^4 and R^5 form, together with the N atom to which they are attached, a 5- or 6-membered saturated N-containing heterocyclic group which includes 0 or 1 additional heteroatoms selected from N, S and O, which may be fused to a benzene ring and which is unsubstituted or substituted; or one of R^4 and R^5 is alkyl and the other is a 5- or 6-membered saturated N-containing heterocyclic group as defined above or an alkyl group which is substituted by a 5- or 6-membered saturated N-containing heterocyclic group as defined above; R^2 is selected from formula (a); wherein R^6 and R^7 form, together with the nitrogen atom to which they are attached, a morpholine, thiomorpholine, piperidine, piperazine, oxazepane or thiazepane group which is unsubstituted or substituted; and formula (b); wherein Y is a C_2-C_4 alkylene chain which contains, between constituent carbon atoms of the chain and/or at one or both ends of the chain, 1 or 2 heteroatoms selected from O, N and S, and which is unsubstituted or substituted; and R^3 is an indazole group which is unsubstituted or substituted; and the pharmaceutically acceptable salt thereof have activity as inhibitors of P13K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with P13 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.

WO 2006/046031 A1

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.